[go: up one dir, main page]

SG156681A1 - Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents

Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Info

Publication number
SG156681A1
SG156681A1 SG200907097-0A SG2009070970A SG156681A1 SG 156681 A1 SG156681 A1 SG 156681A1 SG 2009070970 A SG2009070970 A SG 2009070970A SG 156681 A1 SG156681 A1 SG 156681A1
Authority
SG
Singapore
Prior art keywords
remodeling
ranolazine
treatment
heart failure
combination
Prior art date
Application number
SG200907097-0A
Other languages
English (en)
Inventor
Brent Blackburn
Hani Sabbah
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Publication of SG156681A1 publication Critical patent/SG156681A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG200907097-0A 2004-11-09 2005-11-09 Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure SG156681A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62615404P 2004-11-09 2004-11-09

Publications (1)

Publication Number Publication Date
SG156681A1 true SG156681A1 (en) 2009-11-26

Family

ID=35892429

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200907097-0A SG156681A1 (en) 2004-11-09 2005-11-09 Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure

Country Status (15)

Country Link
US (2) US20060111361A1 (no)
EP (1) EP1809289A1 (no)
JP (1) JP2008519770A (no)
KR (1) KR20070084063A (no)
CN (1) CN101072562A (no)
AU (1) AU2005304421A1 (no)
BR (1) BRPI0517650A (no)
CA (1) CA2586840A1 (no)
IL (1) IL183056A0 (no)
MX (1) MX2007005367A (no)
NO (1) NO20072934L (no)
RU (1) RU2007121707A (no)
SG (1) SG156681A1 (no)
WO (1) WO2006053161A1 (no)
ZA (1) ZA200703697B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
AU2007292923B2 (en) * 2006-09-08 2013-10-03 Cardiopolymers, Inc. Intramyocardial patterning for global cardiac resizing and reshaping
US20080153840A1 (en) * 2006-12-21 2008-06-26 Luiz Belardinelli Reduction of cardiovascular symptoms
CA2677931A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
JP2010518170A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 冠微小血管疾患の処置のためのラノラジンの使用
CA2678325A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of non-coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
CA2682160C (en) * 2007-04-11 2017-04-04 Henry Ford Health System Cardiac repair, resizing and reshaping using the venous system of the heart
EA200971073A1 (ru) * 2007-05-31 2010-08-30 Джилид Пало Альто, Инк. Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа
WO2008154033A2 (en) * 2007-06-11 2008-12-18 Symphony Medical, Inc. Cardiac patterning for improving diastolic function
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
JP2012526848A (ja) * 2009-05-14 2012-11-01 ギリアード サイエンシーズ， インコーポレイテッド Ｃｎｓ障害の治療のためのラノラジン
JP2011010865A (ja) 2009-06-30 2011-01-20 Ikaria Holdings Inc 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法
DK3515523T3 (da) 2016-09-19 2021-05-17 Abiomed Inc Kardiovaskulart hjælpesystem som kvantificerer hjertefunktion og fremmer hjerterestitution

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ247044A (en) * 1989-06-23 1997-04-24 Syntex Usa Inc Substituted For Use of ranolazine and related piperazine derivatives to treat tissue affected by muscle and neuronal damage, including transplant tissue
US20030077229A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US6323226B1 (en) * 1999-10-19 2001-11-27 Texas Heart Institute Treatment of heart disease with cox-2 inhibitors
CN1227004C (zh) * 2000-02-18 2005-11-16 Cv治疗公司 治疗充血性心力衰竭的部分脂肪酸氧化抑制剂
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias

Also Published As

Publication number Publication date
CN101072562A (zh) 2007-11-14
NO20072934L (no) 2007-08-08
US20090176772A1 (en) 2009-07-09
US20060111361A1 (en) 2006-05-25
EP1809289A1 (en) 2007-07-25
IL183056A0 (en) 2007-10-31
RU2007121707A (ru) 2008-12-20
KR20070084063A (ko) 2007-08-24
BRPI0517650A (pt) 2008-10-14
JP2008519770A (ja) 2008-06-12
MX2007005367A (es) 2007-06-18
CA2586840A1 (en) 2006-05-18
WO2006053161A8 (en) 2006-09-14
ZA200703697B (en) 2008-09-25
AU2005304421A1 (en) 2006-05-18
WO2006053161A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
NO20072934L (no) Anvendelse av Ranolazon i kombinasjon med minst ett remodelleringsmiddel for a reversere remodellering av venstre ventikkel ved behandlingen av hjertesvikt
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2009137465A3 (en) Compositions for treatment or prevention of pathological cardiac remodeling and heart failure
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2004010937A3 (en) Method of treating cancer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
AU2459402A (en) Composition
WO2008127594A3 (en) Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
ECSP11011030A (es) Método para tratar o prevenir la trombosis usando etexilato de dabigatrán o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional.
HK1198869A1 (en) Combination treatments for hepatitis c
MX2007002311A (es) Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2021003845A (es) Composiciones para reducir el acido urico serico.
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
MX2010010334A (es) Tratamiento de psoriasis o artritis psoriatica utilizando ciclopropil-n-{2-{(1s)-1-(3-etoxi-4-metoxifenil)-2-(metilsulfonil )etil]-3-oxoisoindolina-4-il}carboxamida.
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
BRPI0518700B8 (pt) combinação contendo vegf-trap, 5-fluorouracila e ácido folínico